Mesalazine-associated severe aplastic anemia successfully treated with antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor

International Journal of Hematology

Volumn 68, Issue 4, 1998, Pages 445-448

  Otsubo, Hiroko ^a   Kaito, Ken ^a   Sekita, Toru ^a   Shimada, Takaki ^a   Kobayashi, Masayuki ^a   Hosoya, Tatsuo ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithymocyte globulin; Aplastic anemia; Cyclosporine; Granulocyte colony stimulating factor; Mesalazine

Indexed keywords

CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOGLOBULINE; MESALAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0031774239     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00082-6     Document Type: Article

References (15)

1. Aymard J.P., Aymard B., Netter P., Bannwarth B., Trechot P., Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med. Toxicol. 3:1988;430-448.
2. Liersh T., Beyer J.H., Krieger G., Vehmeyer K. The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine. Ann. Hematol. 64:1992;231-239.
3. Jick H., Myers M.W., Dean A.D. The risk of sulfasalazine and mesalazine-associated blood disorders. Pharamacotherapy. 15:1995;176-181.
4. Daneshmend T.K. Mesalazine-associated thrombocytopenia. Lancet 1991;337:1297-1298.
5. Wyatt S., Joyner M.V., Daneshmend T.K. Filgastim for mesalazine-associated neutropenia. Lancet. 341:1993;1476.
6. Abboudi Z.H., Marsh J.C.W., Smith-Laing G., Gordon-Smith E.C. Fatal aplastic anemia after mesalazine. Lancet. 343:1994;542.
7. Laidlaw S.T., Reilly J.T. Antilymphocyte globulin for mesalazine-associated aplastic anemia. Lancet. 343:1994;981-982.
8. Kaufman D.W., Kelly J.P., Jurgelon J.M., Anderson T., Issaragrisil S., Wiholm B.E., Young N.S., Leaverton P., Levy M., Shapiro S. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur. J. Haematol. 1996;57 Suppl:31-34.
9. Class F.H.J. Immune mechanisms leading to drug-induced blood dyscrasias. Eur. J. Haematol. 1996;57 Suppl:64-68.
10. Nakao S. Immune mechanism of aplastic anemia. Int. J. Hematol. 66:1997;127-134.
11. Champlin R., Ho W., Gale R.P. Antithymocyte globulin treatment in patients with aplastic anemia. New Engl. J. Med. 308:1983;113-118.
12. Marsh J.C.W., Gordon-Smith E.C. Treatment of aplastic anemia with antilymphocyte globulin and cyclosporin. Int. J. Hematol. 62:1995;133-144.
13. Frickhofen N., Kaltwasser J.P., Schrezenmeier H., Raghavachar A., Vogt H.G., Herrmann F., Freund M., Meusers P., Salama A., Heimpel H. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. New Engl. J. Med. 324:1991;1297-1304.
14. Rosenfeld S., Kimball J., Vining D., Young N.S. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 85:1995;3058-3065.
15. Bacigalupo A., Broccia G., Corda G., Arcese W., Carotenuto M., Gallamini A., Locatelli F., Mori P.G., Saracco P., Todeschini G., Coster P., Lacopino P., van Lint M.T., Gluckman E. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party. Blood. 85:1995;1348-1353.